KPC Pharmaceuticals (600422) Fundamentals 2026 — P/E 59.9x, Revenue Analysis | SniperIQ
KPC Pharmaceuticals (600422) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.7B, trading at ¥8.91 on the SHH. This SniperIQ fundamentals page covers KPC Pharmaceuticals's valuation (P/E 59.9x, P/B 1.3x), profitability (net margin 2.0%), revenue (¥6.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is KPC Pharmaceuticals's market cap?
KPC Pharmaceuticals (600422) has a market capitalization of approximately ¥6.7B, trading at ¥8.91 on the SHH. Market cap moves with the live share price.
What is KPC Pharmaceuticals's P/E ratio?
KPC Pharmaceuticals's trailing twelve-month P/E ratio is 59.9x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is KPC Pharmaceuticals?
KPC Pharmaceuticals runs a net profit margin of 2.0%, a gross margin of 0.7%, and an operating margin of 1.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does KPC Pharmaceuticals generate?
KPC Pharmaceuticals reported revenue of ¥6.6B for fiscal year 2025, with net income of ¥350M and earnings per share (EPS) of 0.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does KPC Pharmaceuticals pay a dividend?
KPC Pharmaceuticals offers a trailing dividend yield of about 3.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is KPC Pharmaceuticals financially healthy?
KPC Pharmaceuticals carries a debt-to-equity ratio of 0.36x and a current ratio of 2.09x, with a market beta of -0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is KPC Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For KPC Pharmaceuticals (600422) the key facts are: market cap ¥6.7B, P/E 59.9x, revenue ¥6.6B, 52-week range 7.45-15.08. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track KPC Pharmaceuticals's full fundamentals live
Get KPC Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.